TY - JOUR
T1 - Clinical characteristics of fulminant-type autoimmune hepatitis
T2 - An analysis of eleven cases
AU - Miyake, Y.
AU - Iwasaki, Y.
AU - Terada, R.
AU - Onishi, T.
AU - Okamoto, R.
AU - Sakai, N.
AU - Sakaguchi, K.
AU - Shiratori, Y.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2006/5
Y1 - 2006/5
N2 - Background: Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. Aim: To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. Methods: Eleven patients (10%) diagnosed with fulminant-type autoimmune hepatitis in accordance with the 1999 criteria of the International Autoimmune Hepatitis Group were analysed. Results: All 11 patients were female, with a median age of 53 years. Five patients survived without liver transplantation, one received a liver transplantation, and five died without liver transplantation. Nine patients (82%) survived for 2 weeks or more following diagnosis, without liver transplantation. Except for the patient receiving a liver transplantation, serum total bilirubin levels measured during the clinical course were significantly higher in non-survivors than in survivors, although the accompanying serum alanine aminotransferase levels measured for the two groups were similar. Most significantly, serum total bilirubin levels in non-survivors worsened during days 8-15, while levels in survivors improved during the same period. Conclusions: The short-term prognosis for patients with fulminant-type autoimmune hepatitis may be good. However, patients whose serum total bilirubin levels worsen during days 8-15 should be considered forq2 liver transplantation.
AB - Background: Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. Aim: To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. Methods: Eleven patients (10%) diagnosed with fulminant-type autoimmune hepatitis in accordance with the 1999 criteria of the International Autoimmune Hepatitis Group were analysed. Results: All 11 patients were female, with a median age of 53 years. Five patients survived without liver transplantation, one received a liver transplantation, and five died without liver transplantation. Nine patients (82%) survived for 2 weeks or more following diagnosis, without liver transplantation. Except for the patient receiving a liver transplantation, serum total bilirubin levels measured during the clinical course were significantly higher in non-survivors than in survivors, although the accompanying serum alanine aminotransferase levels measured for the two groups were similar. Most significantly, serum total bilirubin levels in non-survivors worsened during days 8-15, while levels in survivors improved during the same period. Conclusions: The short-term prognosis for patients with fulminant-type autoimmune hepatitis may be good. However, patients whose serum total bilirubin levels worsen during days 8-15 should be considered forq2 liver transplantation.
UR - http://www.scopus.com/inward/record.url?scp=33645703754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645703754&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2006.02894.x
DO - 10.1111/j.1365-2036.2006.02894.x
M3 - Article
C2 - 16629940
AN - SCOPUS:33645703754
SN - 0269-2813
VL - 23
SP - 1347
EP - 1353
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 9
ER -